JCEM: Lipoprotein M and Type 2 Diabetes Risk

Recent studies have found that lipoprotein M (apoM) plays a role in energy metabolism, and observational analysis of the human body suggests that it is related to type 2diabetes, but the causal relationship is still difficult to determineRecently, the authoritative journal Journal of Endocrine and Metabolic Diseases published a study in the Journal of Clinical Endocrinology and Metabolism aimed at clarifying whether reduced plasma apoM concentrations are associated with an increased risk of type 2 diabetesthe study was designed for a prospective study of Mendel RandomanalysisTwo queues that reflect the danish population: the Copenhagen Heart Study (CCHS, n-8589) and the Copenhagen General Population Study (CGPS; n-93857)The observational analysis included a subset of participants available from the plasma apoM data in CCHS (n-725)Genetic analysis includes the entire queue (n-102446)During the 16-year (CCHS) and 8-year (CGPS) median follow-up, 563 and 2,132 participants developed type 2 diabetesThe main observations of the study were plasma apoM concentration, genetic variation in APOM, and type 2 diabetesfirst, the researchers determined a negative correlation between plasma apoM and type 2 diabetes risk from the CCHS subgroup (the risk ratio between the highest quartile and the lowest quartile (reference) was 0.32; 95% CI was 0.1-1.01; trend p.02)Secondly, the specific SNP genotypes in APOM further revealed a 10.8% reduction in plasma apoM concentration in subjects with the rs1266078 mutation (p-6.2e-5)Third, a meta-analysis of data from 599,451 individuals found no association between rs1266078 and the risk of type 2 diabetes, this study does not seem to support a causal relationship between plasma apoM and the risk of type 2 diabetes